Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically
Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy
Positive high-level results from the FLAURA2 Phase III trial. | May 17, 2023